Eurofins enhances its CDMO capacities

| By | API, CDMO, Drug Development, GMP Standards, R&D

Eurofins Scientific recently enhanced its leadership in biopharmaceutical services and expanded its Contract Development and Manufacturing (CDMO) offering with several strategic acquisitions.

Eurofins Alphora is a premier, full-service contract research, development and manufacturing organisation (CDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs). Based in Mississauga, Ontario, Canada, with more than 145 employees and facilities totaling more than 5,500 m2, Alphora offers a full spectrum of complex API development, testing and manufacturing services, including extensive capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs.

Eurofins Advinus is a leading preclinical contract research company for Safety Assessment, DMPK, and CMC services, offering end-to-end solutions in the areas of preclinical toxicology testing, API process development and scale up, analytical R&D, drug metabolism and pharmacokinetics, as well as long-term nonclinical toxicology testing, including carcinogenicity studies. The company also supports early clinical development through multi kilo scale API synthesis under cGMP. With over 25 years of GLP compliance and certification, Eurofins Advinus has more than 380 staff and operates a state-of-the art 20,000 m2 facility in Bangalore, India.

Eurofins Amatsigroup is one of the leading CDMOs in Europe providing high-quality, customised drug development solutions for specialty and biopharma clients, including bioprocess development, biomanufacturing, analytical studies, formulation development and manufacturing (Fill & Finish capacities) of clinical or small commercial batches, as well as complementary services such as preclinical studies, bioanalysis and clinical trial supply. GLP & GMP certified, Eurofins Amatsigroup employs 400 staff and operates eight sites in France, two sites in Belgium and one site in the US, totaling more than 28,000 m2.

With the addition of these acquisitions into Eurofins’ existing sterile and non-sterile manufacturing sites in the US and Europe, Eurofins is able to support biopharmaceutical companies from the preclinical phase through to commercialisation of niche products. Further, Eurofins can address a wide array of development challenges with a full spectrum of complex drug substance and drug product development, testing and manufacturing services. Globally, Eurofins is well-positioned to support the growing R&D outsourcing needs throughout the North American, European and Asia-Pacific regions.

SOURCE: eurofins
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.